REG - Creo Medical Group - Exercise of Options

Creo MedicalAnnouncement

04/08/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220804:nRSD8536Ua&default-theme=true

RNS Number : 8536U  Creo Medical Group PLC  04 August 2022

 Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Exercise of Options, PDMR Dealing, Issue of Equity and TVR

 

Creo Medical Group plc (AIM: CREO), the medical device company, focused on the
emerging field of surgical endoscopy, announces that it has received notice of
exercise of options ("Options") under the Company's share option scheme from
John Bradshaw, senior independent non-executive director and a PDMR, to
subscribe for a total of 105,947 new ordinary shares of 0.1 pence each in the
capital of the Company ("Ordinary Shares").  27,000 of the Options are to be
exercised at a price of £0.21389 per Ordinary Share, and 78,947 Options are
to be exercised at a price of £0.76 per Ordinary Share.

 

Application has been made for the admission of 105,947 new Ordinary Shares to
trading on AIM ("Admission").  It is expected that Admission will occur at
8:00 a.m. on 10 August 2022.  Following the exercise of the Options, Mr
Bradshaw will hold 105,947 Ordinary Shares in the Company representing
approximately 0.06 percent. of the Company's issued share capital.

 

Mr Bradshaw has confirmed his current intention to hold the Ordinary Shares
and does not intend to sell any Ordinary Shares to meet any tax liability
arising on the exercise of the Options.  Following this transaction, Mr
Bradshaw will hold no share options in the Company.

 

Following Admission, the Company will have 181,527,885 Ordinary Shares in
issue with voting rights attached. The Company has no shares in treasury;
therefore upon, and subject to, registration, the total number of voting
rights in Creo will be 181,527,885.  This figure may be used by shareholders
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change of their interest in,
the Company under the FCA's Disclosure and Transparency Rules.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 1. Details of PDMR
 a)  Name                                     John Bradshaw
 b)  Position / status                        Senior Independent Non-Executive Director
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Exercise of share options

 c)  Price(s) and volume(s)                   Prices                                            Volume(s)
                                              Exercise of share options at £0.21389 per share   27,000

                                              Exercise of share options at £0.76 per share      78,947

 d)  Aggregated information

     Aggregated volume Price

                                              105,947

                                              £65,774.75
 e)  Date of the                              2022-08-03

     transaction
 f)  Place of the transaction                 Off Market

d)

Aggregated information

 

Aggregated volume Price

 

 

 

105,947

£65,774.75

e)

Date of the

transaction

2022-08-03

f)

Place of the transaction

Off Market

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cenkos Securities plc                              +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Joint Broker)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000
 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZGGRGFNGZZZ